:

Department of Research Programs > CancerCenterClinicalTrials
 
Cancer Center Clinical Trials

Standard dose versus high dose versus extended standard dose radium-223 dichloride in castration-resistant prostate cancer metastatic to the bone
Official Title:A three arm randomized, open-label Phase II study of radium-223 dichloride 50 kBq/kg versus 80 kBq/kg versus 50 kBq/kg in an extended dosing schedule in subjects with castration-resistant prostate cancer metastatic to the bone
Date Window: 5/20/2015 - 4/20/2016
Contact for Details:Judith Travis, RN at 301-319-2927 or judith.a.travis.ctr@mail.mil
Summary:​For men with prostate cancer which has metastasized to the bone.  Any prior treatment is allowed, there is no exclusion for taking abiraterone or enzalutamide. Visceral metastases are an exclusion, but some lymph nodes are allowed.  The treatment phase is either 6 or 12 months, then follow-up is lifetime

Imaging in Combat Veterans with Blast Injury and Posttraumatic Stress Disorder
Official Title:The ViRTICo-BP Trials: Virtual Reality Therapy and Imaging in Combat Veterans with Blast Injury and Posttraumatic Stress Disorder
Date Window: 2/27/2007 - 12/31/2015
Contact for Details:Patricia Taylor, (240) 507 6339, patricia.taylor.ctr@usuhs.edu
Summary:The main purpose of this study is to determine whether functional magnetic resonance imaging (fMRI), can distinguish between service members with and without traumatic brain injury (TBI), as well as those with posttraumatic stress disorder (PTSD) who receive either virtual reality exposure therapy (VRET) or "usual care" for their PTSD. We have previously shown in another study that exposure therapy significantly improves function in the brain, and we are now trying to see if this effect is unique to exposure therapy, or also occurs with other treatments. We have also seen links between structural changes in the brain in those with traumatic brain injury (TBI), and brain function as measured by fMRI,  and in turn with PTSD symptoms. However, we need to confirm these findings in larger numbers, and also hope to see whether there is something significantly different about those who have PTSD after TBI vs. those in whom it does not follow a TBI.

GOG 0263
Official Title:GOG 0263: Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery
Date Window: 9/18/2013 - 9/18/2018
Contact for Details:Karen Harrington, karen.m.harrington.civ@health.mil
Summary:This randomized phase III trial is studying giving radiation therapy together with chemotherapy to see how well it works compared to radiation therapy alone in treating patients with stage I or stage II cervical cancer who previously underwent surgery.

Active Comparator: Arm I: Patients undergo pelvic EBRT or IMRT once daily, 5 days a week, for 5½ weeks.

 

Experimental: Arm II: Patients receive cisplatin IV over 1-2 hours on day 1 and undergo radiotherapy as in Arm I. Treatment with cisplatin repeats every 7 days for up to 6 weeks in the absence of disease progression or unacceptable toxicity.


GOG 0274
Official Title:GOG 0274: Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer
Date Window: 9/18/2013 - 9/18/2018
Contact for Details:Karen Harrington (karen.m.harrington.civ@health.mil)
Summary:This randomized phase III trial studies how well giving cisplatin and radiation therapy together with or without carboplatin and paclitaxel works in treating patients with locally advanced cervical cancer.

Active Comparator: Arm I: Patients receive cisplatin IV over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate, pulsed-dose rate, or low-dose rate intracavitary brachytherapy.

Experimental: Arm II: Patients receive cisplatin and undergo external-beam radiation and brachytherapy as in arm I. Beginning 4 weeks later, patients also receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.


GOG 0261
Official Title:GOG 0261: Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed Persistent or Recurrent Uterine or Ovarian Cancer
Date Window: 9/18/2013 - 9/18/2018
Contact for Details:Karen Harrington (karen.m.harrington.civ@health.mil)
Summary:This randomized phase III trial is studying giving paclitaxel together with carboplatin to see how well it works compared with giving paclitaxel together with ifosfamide in treating patients with newly diagnosed persistent or recurrent uterine or ovarian cancer.

Experimental: Arm I:  Patients receive paclitaxel IV over 3 hours and carboplatin IV over 30-60 minutes on day 1.

Experimental: Arm II:  Patients receive paclitaxel as in arm I and ifosfamide IV over 1 hour on days 1-3.


GOG 0258
Official Title:GOG 258: Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
Date Window: 9/18/2013 - 9/19/2018
Contact for Details:Karen Harrington (karen.m.harrington.civ@health.mil)
Summary:This randomized phase III trial is studying carboplatin and paclitaxel to see how well they work when given with or without cisplatin and radiation therapy in treating patients with stage I, stage II, stage III, or stage IVA endometrial cancer.

Experimental: Arm I:  Patients receive cisplatin IV on days 1 and 29. Patients also undergo external-beam radiotherapy once daily, 5 days a week, for 5-6 weeks. Some patients may then undergo brachytherapy over 2-3 weeks. Beginning within 8 weeks after completion of chemoradiotherapy, patients receive paclitaxel IV over 3 hours and carboplatin IV on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
 
Experimental: Arm II:  Patient receive paclitaxel IV over 3 hours and carboplatin IV on day 1.  Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
 
 


Proton Therapy in Larger Doses/Fewer Treatments for Low and Intermediate Risk Cancer of the Prostate
Official Title:A Trial of Proton Radiation Therapy or Intensity Modulated Radiation Therapy Using MildHypofractionation for Low and Intermediate-Risk Adenocarcinoma of the Prostate
Date Window: 5/30/2012 - 5/30/2020
Contact for Details:Jean Petrov, RN MS (301) 295-5010; Kathleen Noel, RN MS (301) 400-0507
Summary:The purpose is to determine toxicities, freedom from failure, safety of the proton radiation therapy treatment and the quality of life with proton therapy in the treatment of low and intermediate-risk adenocarcinoma of the prostate.

http://www.ClinicalTrials.gov (NCT01352429)


Proton Radiation Therapy for Low Risk and Low-Intermediate Risk Cancer of the Prostate
Official Title:A Trial of Proton Radiation Therapy Using Standard Fractionation for Low Risk and Low-Intermediate Risk Adenocarcinoma of the Prostate
Date Window: 11/30/2010 - 11/30/2020
Contact for Details:Jean Petrov, RN MS (301) 295-5010; Kathleen Noel, RN MS (301) 400-0507
Summary:The purpose is to determine the toxicities, safety of the proton radiation therapy and the quality of life with proton therapy in the treatment of low risk and low-intermediate risk adenocarcinoma of the prostate.

http://www.Clinitical Trials.gov (NCT01045226)


Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Subjects With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer
Official Title:GOG 0241: A CGIC Intergroup Multicenter Phase III Trial of Open Label Carboplatin and Paclitaxel +/-NCI Supplied Agent: Bevacizumab Compared with Oxaliplatin & Capecitabine +/- Bevacizumab as 1st Line Chemo in subj w/Mucinous Epithelial Ovarian or Fallop
Date Window: 6/13/2013 - 12/20/2017
Contact for Details:Karen Harrington; karen.m.harrington.civ@health.mil
Summary:

Paclitaxel or Polyglutamate Paclitaxel or Observation in Treating Pts with Stage III or IV Ovarian Epithelial or Peritoneal Cancer or Fallopian Tube Cancer
Official Title:GOG 212: A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or CT 2103 Vs No Treatment until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Ca or Fallopian Tube Ca
Date Window: 6/13/2013 - 6/13/2017
Contact for Details:Karen Harrington, karen.m.harrington.civ@health.mil
Summary:This randomized phase III trial is studying paclitaxel to see how well it works compared to polyglutamate paclitaxel or observation only in treating subjects with stage III or stage IV ovarian epithelial or peritoneal cancer or fallopian tube cancer.  Subjects will be placed in one of three arms of this study:

  • Arm I: Subjects receive polyglutamate paclitaxel IV over 10-20 minutes on day 1.
  • Arm II: Subjects receive paclitaxel IV over 3 hours on day 1.
  • Arm III: Subjects receive no further anticancer treatment until evidence of disease progression.
In arms I and II, treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, before courses 3, 5, and 7 of study treatment, at completion of study treatment, and then at 1 year after completion of study treatment.
After completion of study treatment, subjects are followed every 3 months for 2 years and then every 6 months for 3 years.


1 - 10 Next

Contact

Location
Building 17B
3rd Floor, Suite E

Phone
Main (301) 295-8239/8219

Hours of Operation
Monday thru Friday
0700 - 1630